A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research, published in Annals of Oncology, found that GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing cancer among non-diabetic patients who used the drugs for weight management, compared to those who relied on diet and exercise alone.

AI-powered atlas uncovered tertiary lymphoid structures as prognostic biomarkers

Research reveals drivers of treatment resistance in KRAS-mutant colorectal cancer and insights on which patients may benefit most from immunotherapy for various cancers

Scientists uncover the molecular pathways involved in blood vessel plaques

Immunotherapy could help treat potentially fatal fungal pneumonias  

Direct-to-consumer pharmacies may lower costs for generic prescriptions

About The Study: In this cross-sectional study, early age–onset colorectal cancer (EOCRC) was associated with improved overall survival compared with average age–onset colorectal cancer; however, treatment delays were independently associated with worse survival among patients with EOCRC. Language barriers could be a potentially modifiable risk factor associated with delayed treatment and may provide an opportunity to improve timely care and outcomes in EOCRC. 

After surgery for colon cancer, many patients face the question of whether follow-up chemotherapy is necessary to prevent a possible relapse. The decision is particularly difficult in so-called Stage II, the intermediate-risk group: Although around one in five untreated patients suffers a relapse, adjuvant chemotherapy places a significant and, in some cases, unnecessary burden on many patients. A large clinical study led by Dresden University Hospital (UKD) now provides important insights for a robust basis for decision-making. These findings were presented for the first time at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) and published simultaneously in the Annals of Oncology.

Colorectal cancer is the second leading cause of death from cancer in the United States. Recent research pointed to stem cells as a significant primary driver of colorectal cancer, but exactly what happens at the cellular level inside the gut is less clear. A new study by researchers at Stevens Institute of Technology sheds, outlines a mechanism by which colorectal cancers can evolve from mature intestinal cells that revert to stem cells and suggests pathways for effective therapies.